XELJANZ® (tofacitinib citrate) receives marketing authorisation in the European Union for the treatment of moderate to severe active rheumatoid arthritis
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) announced today that the European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) oral tablets in combination with methotrexate (MTX) for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).
Bayer's Rivaroxaban demonstrated superior protection against recurrent venous thromboembolism compared with Aspirin in EINSTEIN CHOICE study
- Details
- Category: Bayer
Bayer AG and its development partner Janssen Pharmaceuticals, Inc. have announced results from the EINSTEIN CHOICE study, which demonstrated that both 10 mg and 20 mg once-daily dosages of its oral Factor Xa inhibitor rivaroxaban (Xarelto®) significantly reduced the risk of recurrent venous thromboembolism (VTE) compared with aspirin 100 mg once daily (acetylsalicylic acid, ASA) in patients who had previously completed 6 to 12 months of anticoagulation therapy for pulmonary embolism (PE) or symptomatic deep vein thrombosis (DVT).
Novartis' Cosentyx is first and only IL-17A inhibitor to potentially modify the course of psoriasis
- Details
- Category: Novartis
Novartis has announced new data suggesting, for the first time, that Cosentyx® (secukinumab) may modify the course of moderate-to-severe psoriasis leading to long-term, treatment-free skin clearance[1]. Cosentyx is the first and only IL-17A inhibitor to have reported this potential of disease modification.
Merck Accelerator hits new peak of applications
- Details
- Category: Merck Group
Merck, a leading science and technology company, announced today the new startups participating in its Accelerator programs in Darmstadt, Germany and Nairobi, Kenya. The two program locations accept startups from different fields within Merck's core specialisms: Darmstadt takes startups from the fields of healthcare, life sciences and performance materials, while Nairobi works exclusively on innovations in digital healthcare.
New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes
- Details
- Category: Novartis
Novartis has announced results of a new post-hoc analysis in a subgroup of patients with reduced ejection fraction heart failure (HFrEF) and diabetes suggesting that Entresto® (sacubitril/valsartan) tablets improved glycemic control, as assessed by hemoglobin A1c (HbA1c) testing, compared to ACE-inhibitor enalapril[1].
Landmark outcomes study shows that Repatha® (Evolocumab) decreases LDL-C to unprecedented low levels and reduces risk of cardiovascular events
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) today announced that the 27,564-patient Repatha® (evolocumab) cardiovascular outcomes study, FOURIER, established for the first time that maximally reducing low-density lipoprotein cholesterol (LDL-C) levels with Repatha, beyond what is possible with the current best therapy alone, leads to a further reduction in major cardiovascular events, including heart attacks, strokes and coronary revascularizations.
AstraZeneca and Circassia enter strategic collaboration in respiratory disease
- Details
- Category: AstraZeneca
AstraZeneca today announced it has entered a strategic collaboration with Circassia Pharmaceuticals plc, a respiratory biopharmaceutical company, for the development and commercialisation of Tudorza and Duaklir* in the US. Tudorza and Duaklir are inhaled respiratory medicines for the treatment of chronic obstructive pulmonary disease (COPD).
More Pharma News ...
- Johnson & Johnson reports that investigational Ebola vaccine regimen induced durable immune response 1 year after vaccination in Phase 1 study
- LEO Innovation Lab CEO wins eyeforpharma Customer Innovator Award
- Roche Annual General Meeting 2017
- Sandoz announces winners of inaugural Healthcare Access Challenge #SandozHACk
- The Union for International Cancer Control and Pfizer announce next phase of global grants initiative supporting metastatic breast cancer patients
- Boehringer Ingelheim expands collaboration with Vanderbilt University to tackle some of the most difficult-to-treat cancers
- MedImmune and Sanofi Pasteur form alliance to develop and commercialise potential next-generation respiratory syncytial virus antibody MEDI8897